Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
32.60
+2.76 (9.25%)
At close: Oct 20, 2026, 4:00 PM EDT
33.19
+0.59 (1.81%)
Pre-market: Oct 21, 2026, 4:01 AM EDT
Immunocore Holdings Revenue
Immunocore Holdings had revenue of $314.85M in the twelve months ending June 30, 2026, down -11.60% year-over-year. In the year 2025, Immunocore Holdings had annual revenue of $400.02M with 28.95% growth. That makes Immunocore Holdings the 12,096th largest company in the world by revenue and 2,385th in the United States.
Revenue (ttm)
$314.85M
Revenue Growth
-11.60%
P/S Ratio
3.90
Revenue / Employee
$822,090
Employees
524
Market Cap
1.68B
Revenue by Geography
- United States 257.00M 64.2%
- Europe 131.42M 32.9%
- International 11.60M 2.9%
Fiscal year ended Dec 31, 2025 See the full Immunocore Holdings breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 400.02M | 89.81M | 28.95% |
| Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
| Dec 31, 2023 | 249.43M | 75.53M | 43.44% |
| Dec 31, 2022 | 173.89M | 138.04M | 384.99% |
| Dec 31, 2021 | 35.85M | -5.32M | -12.91% |
| Dec 31, 2020 | 41.17M | 7.13M | 20.95% |
| Dec 31, 2019 | 34.04M | 3.91M | 12.98% |
| Dec 31, 2018 | 30.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 440.00M |
| Nuvation Bio | 169.90M |
| Ocular Therapeutix | 52.06M |
| Stoke Therapeutics | 27.59M |
| Generate Biomedicines | 26.48M |
| Maze Therapeutics | 20.00M |
| uniQure | 18.67M |
IMCR News
- 5 days ago - Immunocore doses first patient in IMC-S118AI trial - TheFly
- 5 days ago - Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes - GlobeNewsWire
- 5 weeks ago - Immunocore Holdings Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 weeks ago - Immunocore achieves target patient enrollment in TEBE-AM clinical trial - TheFly
- 5 weeks ago - Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma - GlobeNewsWire
- 5 weeks ago - Immunocore Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 7 weeks ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 2 months ago - Immunocore reinstated with an Overweight at JPMorgan - TheFly